Search
Edasalonexent
go.drugbank.com/drugs/DB15010InvestigationalEdasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).
Vunakizumab
go.drugbank.com/drugs/DB15154InvestigationalVunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
Ofranergene obadenovec
go.drugbank.com/drugs/DB15175InvestigationalOfranergene obadenovec is under investigation in clinical trial NCT01229865 (Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer).
ATB-346
go.drugbank.com/drugs/DB15377InvestigationalATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).
SP-420
go.drugbank.com/drugs/DB16069InvestigationalSP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent Beta-thalassemia or Other Rare Anemias).
ISIS 2503
go.drugbank.com/drugs/DB16181InvestigationalISIS 2503 is under investigation in clinical trial NCT00004193 (ISIS 2503 in Treating Patients With Metastatic And/or Locally Recurrent Colorectal Cancer).
Felzartamab
go.drugbank.com/drugs/DB16375InvestigationalFelzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
Daxdilimab
go.drugbank.com/drugs/DB16391InvestigationalDaxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
Autogene cevumeran
go.drugbank.com/drugs/DB17497InvestigationalAutogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
Alintegimod
go.drugbank.com/drugs/DB18879InvestigationalAlintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).